In a phase III clinical trial involving 405 patients with stage IIIB/IV NSCLC, patients were randomized to receive CIMAvax‐EGF (vaccine) or best supportive care (control) 4 to 6 weeks after first‐line chemotherapy. This evidence concerns the gene EGF and non-small cell lung carcinoma.